Volume 10 Issue 5
Sep.  2019
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2019  >  10(5): 559-569
Li Ning. Mineral and bone abnormalities after renal transplantation[J]. ORGAN TRANSPLANTATION, 2019, 10(5): 559-569. doi: 10.3969/j.issn.1674-7445.2019.05.016
Citation: Li Ning. Mineral and bone abnormalities after renal transplantation[J]. ORGAN TRANSPLANTATION, 2019, 10(5): 559-569. doi: 10.3969/j.issn.1674-7445.2019.05.016
shu

Mineral and bone abnormalities after renal transplantation

doi: 10.3969/j.issn.1674-7445.2019.05.016
  • Received Date: 2019-06-18
    Available Online: 2021-01-19
  • Publish Date: 2019-09-15
    Abstract
    • FullText(HTML)
  • loading
    • References(64)
  • [1]
    VANGALA C, PAN J, COTTON RT, et al. Mineral and bone disorders after kidney transplantation[J]. Front Med (Lausanne), 2018, 5:211. DOI: 10.3389/fmed.2018.00211.
    [2]
    AMIN T, COATES PT, BARBARA J, et al. Prevalence of hypercalcaemia in a renal transplant population: a single centre study[J]. Int J Nephrol, 2016:7126290. DOI: 10.1155/2016/7126290.
    [3]
    WOLF M, WEIR MR, KOPYT N, et al. A prospective cohort study of mineral metabolism after kidney transplantation[J]. Transplantation, 2016, 100(1):184-193. DOI: 10.1097/TP.0000000000000823.
    [4]
    SAVAJ S, GHODS FJ. Vitamin D, parathyroid hormone, and bone mineral density status in kidney transplant recipients[J]. Iran J Kidney Dis, 2012, 6(4):295-299.
    [5]
    EGBUNA OI, TAYLOR JG, BUSHINSKY DA, et al. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure[J]. Clin Transplant, 2007, 21(4):558-566. doi: 10.1111/j.1399-0012.2007.00690.x
    [6]
    RAMEZANI M, EINOLLAHI B, ASL MA, et al. Calcium and phosphorus metabolism disturbances after renal transplantation[J]. Transplant Proc, 2007, 39(4):1033-1035. doi: 10.1016/j.transproceed.2007.03.025
    [7]
    KIM YJ, KIM MG, JEON HJ, et al. Clinical manifestations of hypercalcemia and hypophosphatemia after kidney transplantation[J]. Transplant Proc, 2012, 44(3):651-656. DOI: 10.1016/j.transproceed.2011.12.050.
    [8]
    GWINNER W, SUPPA S, MENGEL M, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications[J]. Am J Transplant, 2005, 5(8):1934-1941. doi: 10.1111/j.1600-6143.2005.00938.x
    [9]
    ALSHAYEB HM, JOSEPHSON MA, SPRAGUE SM. CKD-mineral and bone disorder management in kidney transplant recipients[J]. Am J Kidney Dis, 2013, 61(2):310-325. DOI: 10.1053/j.ajkd.2012.07.022.
    [10]
    BARROS X, FUSTER D, PASCHOALIN R, et al. Changes in bone mineral metabolism parameters, including FGF23, after discontinuing cinacalcet at kidney transplantation[J]. Endocrine, 2015, 49(1):267-273. DOI: 10.1007/s12020-014-0400-1.
    [11]
    EVENEPOEL P, COOPER K, HOLDAAS H, et al. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism[J]. Am J Transplant, 2014, 14(11):2545-2555. DOI: 10.1111/ajt.12911.
    [12]
    SPRAGUE SM, BELOZEROFF V, DANESE MD, et al. Abnormal bone and mineral metabolism in kidney transplant patients--a review[J]. Am J Nephrol, 2008, 28(2):246-253. doi: 10.1159/000110875
    [13]
    BAIA LC, HEILBERG IP, NAVIS G, et al. Phosphate and FGF-23 homeostasis after kidney transplantation[J]. Nat Rev Nephrol, 2015, 11(11):656-666. DOI: 10.1038/nrneph.2015.153.
    [14]
    VAN LONDEN M, AARTS BM, DEETMAN PE, et al. Post-transplant hypophosphatemia and the risk of death-censored graft failure and mortality after kidney transplantation[J]. Clin J Am Soc Nephrol, 2017, 12(8):1301-1310. DOI: 10.2215/CJN.10270916.
    [15]
    JEON HJ, KIM YC, PARK S, et al. Association of serum phosphorus concentration with mortality and graft failure among kidney transplant recipients[J]. Clin J Am Soc Nephrol, 2017, 12(4):653-662. DOI: 10.2215/CJN.07090716.
    [16]
    TATARANNI T, BIONDI G, CARIELLO M, et al. Rapamycin-induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and Klotho expression[J]. Am J Transplant, 2011, 11(8):1656-1664. DOI: 10.1111/j.1600-6143.2011.03590.x.
    [17]
    TOMIDA K, HAMANO T, ICHIMARU N, et al. Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation[J]. Bone, 2012, 51(4):729-736. DOI: 10.1016/j.bone.2012.06.027.
    [18]
    LOU I, FOLEY D, ODORICO SK, et al. How well does renal transplantation cure hyperparathyroidism?[J]. Ann Surg, 2015, 262(4):653-659. DOI: 10.1097/SLA.0000000000001431.
    [19]
    MOLNAR MZ, KOVESDY CP, MUCSI I, et al. Association of pre-kidney transplant markers of mineral and bone disorder with post-transplant outcomes[J]. Clin J Am Soc Nephrol, 2012, 7(11):1859-1871. DOI: 10.2215/CJN.01910212.
    [20]
    KOVÁCS DÁ, FEDOR R, ASZTALOS L, et al. Surgical treatment of hyperparathyroidism after kidney transplant[J]. Transplant Proc, 2019, 51(4):1244-1247. DOI: 10.1016/j.transproceed.2019.03.008.
    [21]
    HEAF J, TVEDEGAARD E, KANSTRUP IL, et al. Hyperparathyroidism and long-term bone loss after renal transplantation[J]. Clin Transplant, 2003, 17(3):268-274. doi: 10.1034/j.1399-0012.2003.00047.x
    [22]
    RODRIGUEZ M, NEMETH E, MARTIN D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism[J]. Am J Physiol Renal Physiol, 2005, 288(2):F253-F264. doi: 10.1152/ajprenal.00302.2004
    [23]
    TABIBZADEH N, CHAVAROT N, FLAMANT M, et al. Biphosphonate therapy, risk of fracture, and sites of bone mineral density assessments in kidney transplantation[J]. J Am Soc Nephrol, 2019, 30(5):905. DOI: 10.1681/ASN.2019010079.
    [24]
    BOUQUEGNEAU A, SALAM S, DELANAYE P, et al. Bone disease after kidney transplantation[J]. Clin J Am Soc Nephrol, 2016, 11(7):1282-1296. DOI: 10.2215/CJN.11371015.
    [25]
    KOCH NOGUEIRA PC, DAVID L, COCHAT P. Evolution of secondary hyperparathyroidism after renal transplantation[J]. Pediatr Nephrol, 2000, 14(4):342-346. doi: 10.1007/s004670050772
    [26]
    TIOSANO D, HOCHBERG Z. Hypophosphatemia: the common denominator of all rickets[J]. J Bone Miner Metab, 2009, 27(4):392-401. DOI: 10.1007/s00774-009-0079-1.
    [27]
    VAUTOUR LM, MELTON LJ 3RD, CLARKE BL, et al. Long-term fracture risk following renal transplantation: a population-based study[J]. Osteoporos Int, 2004, 15(2):160-167. doi: 10.1007/s00198-003-1532-y
    [28]
    王泰娜, 徐斌, 贾凤玉, 等.帕立骨化醇治疗血液透析患者伴继发性甲状旁腺功能亢进[J].肾脏病与透析肾移植杂志, 2015, 24(1):1-5. http://d.old.wanfangdata.com.cn/Periodical/szbytxsyzzz201501001

    WANG TN, XU B, JIA FY, et al. Treatment of secondary hyperparathyroidism in hemodilysis patients by paricalcitol[J]. Chin J Nephrol Dial Transplant, 2015, 24(1):1-5. http://d.old.wanfangdata.com.cn/Periodical/szbytxsyzzz201501001
    [29]
    SZWARC I, ARGILÉS A, GARRIGUE V, et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism[J]. Transplantation, 2006, 82(5):675-680. doi: 10.1097/01.tp.0000232452.80018.ad
    [30]
    Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD update work group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Kidney Int Suppl, 2017, 7(3):1-59. DOI: 10.1016/j.kisu.2017.10.001.
    [31]
    CUNNINGHAM J, LOCATELLI F, RODRIGUEZ M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options[J]. Clin J Am Soc Nephrol, 2011, 6(4):913-921. DOI: 10.2215/CJN.06040710.
    [32]
    RAGGI P, CHERTOW GM, TORRES PU, et al. The advance study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis[J]. Nephrol Dial Transplant, 2011, 26(4):1327-1339. DOI: 10.1093/ndt/gfq725.
    [33]
    FALCK P, VETHE NT, ASBERG A, et al. Cinacalcet' s effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients[J]. Nephrol Dial Transplant, 2008, 23(3):1048-1053.
    [34]
    LORENZ K, BARTSCH DK, SANCHO JJ, et al. Surgical management of secondary hyperparathyroidism in chronic kidney disease--a consensus report of the European Society of Endocrine Surgeons[J]. Langenbecks Arch Surg, 2015, 400(8):907-927. DOI: 10.1007/s00423-015-1344-5.
    [35]
    国家肾脏疾病临床医学研究中心.中国慢性肾脏病矿物质和骨异常诊治指南概要[J].肾脏病与透析肾移植杂志, 2019, 28(1):52-57. DOI:10.3969/j.issn.1006-298X. 2019.01.012.

    National Clinical Research Center For Kidney Disease. Summary of guidelines for the diagnosis and treatment of mineral and bone abnormalities in chronic kidney disease in China[J]. Chin J Nephrol Dial Transplant, 2019, 28(1):52-57.DOI: 10.3969/j.issn.1006-298X.2019.01.012.
    [36]
    罗丽花, 管保章, 黄盛玲, 等.微波消融治疗继发性甲状旁腺功能亢进2例的短期疗效观察[J].中华肾脏病杂志, 2015, 31(4):312-313.DOI: 10.3760/cma.j.issn.1001-7097.2015.04.016.

    LUO LH, GUAN BZ, HUANG SL, et al. The short-term effect of microwave ablation on 2 cases of secondary hyperparathyroidism[J]. Chin J Nephrol, 2015, 31(4):312-313.DOI: 10.3760/cma.j.issn.1001-7097.2015.04.016.
    [37]
    HOLICK MF. Vitamin D deficiency[J]. N Engl J Med, 2007, 357(3):266-281. doi: 10.1056/NEJMra070553
    [38]
    RIZVI SM, VEIERØD MB, THORSBY PM, et al. Vitamin D in Norwegian renal transplant recipients: a longitudinal study with repeated measurements in winter and summer[J]. Eur J Dermatol, 2015, 25(3):234-239. DOI: 10.1684/ejd.2015.2524.
    [39]
    BIENAIMÉ F, GIRARD D, ANGLICHEAU D, et al. Vitamin D status and outcomes after renal transplantation[J]. J Am Soc Nephrol, 2013, 24(5):831-841. DOI: 10.1681/ASN.2012060614.
    [40]
    KEYZER CA, RIPHAGEN IJ, JOOSTEN MM, et al. Associations of 25(OH) and 1, 25(OH)2 vitamin D with long-term outcomes in stable renal transplant recipients[J]. J Clin Endocrinol Metab, 2015, 100(1):81-89. DOI: 10.1210/jc.2014-3012.
    [41]
    LE FUR A, FOURNIER MC, GILLAIZEAU F, et al. Vitamin D deficiency is an independent risk factor for PTDM after kidney transplantation[J]. Transpl Int, 2016, 29(2):207-215. DOI: 10.1111/tri.12697.
    [42]
    ASTOR BC, DJAMALI A, MANDELBROT DA, et al. The association of 25-hydroxyvitamin D levels with late cytomegalovirus infection in kidney transplant recipients: the Wisconsin Allograft Recipient Database[J]. Transplantation, 2019, 103(8):1683-1688. DOI: 10.1097/TP.0000000000002672.
    [43]
    SÁNCHEZ FRUCTUOSO AI, MAESTRO ML, CALVO N, et al. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation[J]. Transplant Proc, 2012, 44(9):2551-2554. DOI: 10.1016/j.transproceed.2012.09.070.
    [44]
    SAITO H, MAEDA A, OHTOMO S, et al. Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo[J]. J Biol Chem, 2005, 280(4):2543-2549. doi: 10.1074/jbc.M408903200
    [45]
    BACIC D, LEHIR M, BIBER J, et al. The renal Na+/phosphate cotransporter NaPi-Ⅱa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone[J]. Kidney Int, 2006, 69(3):495-503. doi: 10.1038/sj.ki.5000148
    [46]
    BRANDENBURG VM, KETTELER M, FASSBENDER WJ, et al. Development of lumbar bone mineral density in the late course after kidney transplantation[J]. Am J Kidney Dis, 2002, 40(5):1066-1074. doi: 10.1053/ajkd.2002.36345
    [47]
    NIKKEL LE, HOLLENBEAK CS, FOX EJ, et al. Risk of fractures after renal transplantation in the United States[J]. Transplantation, 2009, 87(12):1846-1851. DOI: 10.1097/TP.0b013e3181a6bbda.
    [48]
    VAN STAA TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis[J]. Calcif Tissue Int, 2006, 79(3):129-137. doi: 10.1007/s00223-006-0019-1
    [49]
    CANALIS E, MAZZIOTTI G, GIUSTINA A, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy[J]. Osteoporos Int, 2007, 18(10):1319-1328. doi: 10.1007/s00198-007-0394-0
    [50]
    CUETO-MANZANO AM, KONEL S, CROWLEY V, et al. Bone histopathology and densitometry comparison between cyclosporine a monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant patients[J]. Transplantation, 2003, 75(12):2053-2058. doi: 10.1097/01.TP.0000068869.21770.F6
    [51]
    MARTÍN-FERNÁNDEZ M, RUBERT M, MONTERO M, et al. Effects of cyclosporine, tacrolimus, and rapamycin on osteoblasts[J]. Transplant Proc, 2017, 49(9):2219-2224. DOI: 10.1016/j.transproceed.2017.07.005.
    [52]
    SAKAGUCHI Y, HAMANO T, WADA A, et al. Magnesium and risk of hip fracture among patients undergoing hemodialysis[J]. J Am Soc Nephrol, 2018, 29(3):991-999. DOI: 10.1681/ASN.2017080849.
    [53]
    REINHARDT W, KÜBBER H, DOLFF S, et al. Rapid recovery of hypogonadism in male patients with end stage renal disease after renal transplantation[J]. Endocrine, 2018, 60(1):159-166. DOI: 10.1007/s12020-018-1543-2.
    [54]
    LENIHAN CR, SUKUMARAN NAIR S, VANGALA C, et al. Proton pump inhibitor use and risk of hip fracture in kidney transplant recipients[J]. Am J Kidney Dis, 2017, 69(5):595-601. DOI: 10.1053/j.ajkd.2016.09.019.
    [55]
    中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中国骨质疏松杂志, 2019, 25(3):281-309.DOI: 10.3969/j.issn.1006-7108.2019.03.001.

    Branch of Osteoporosis and Bone Mineral Salt Disease of Chinese Medical Association. Guidelines for the diagnosis and management of primary osteoporosis (2017)[J]. Chin J Osteoporos, 2019, 25(3):281-309. DOI: 10.3969/j.issn.1006-7108.2019.03.001.
    [56]
    中华医学会骨质疏松和骨矿盐疾病分会.骨代谢生化标志物临床应用指南[J].中华骨质疏松和骨矿盐疾病杂志, 2015, 8(4):283-293.DOI: 10.3969/j.issn.1674-2591.2015.04.001.

    Branch of Osteoporosis and Bone Mineral Salt Disease of Chinese Medical Association. Clinical application guidelines for biochemical markers of bone metabolism[J]. Chin J Osteoporos Bone Mine Res, 2015, 8(4):283-293. DOI: 10.3969/j.issn.1674-2591.2015.04.001.
    [57]
    KOH LK, SEDRINE WB, TORRALBA TP, et al. A simple tool to identify asian women at increased risk of osteoporosis[J]. Osteoporos Int, 2001, 12(8):699-705. doi: 10.1007/s001980170070
    [58]
    WHO. Assessment of osteoporosis at the primary health care level[EB/OL]. (2015-12-08).http://www.who.int/chp/topics/Osteoporosis.pdf.
    [59]
    SEAMON J, KELLER T, SALEH J, et al. The pathogenesis of nontraumatic osteonecrosis[J]. Arthritis, 2012:601763. DOI: 10.1155/2012/601763.
    [60]
    KERACHIAN MA, SÉGUIN C, HARVEY EJ. Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action[J]. J Steroid Biochem Mol Biol, 2009, 114(3/4/5):121-128. DOI: 10.1016/j.jsbmb.2009.02.007.
    [61]
    李子荣.股骨头坏死临床诊疗规范[J].中华骨与关节外科杂志, 2015, 387(1):1-6.DOI: 10.3969/j.issn.2095-9958.2015.01-001.

    LI ZR. Clinical diagnosis and treatment specification of femoral head necrosis[J]. Chin J Bone Joint Surg, 2015, 387(1):1-6. DOI: 10.3969/j.issn.2095-9958.2015.01-001.
    [62]
    OJO AO, MORALES JM, GONZÁLEZ-MOLINA M, et al. Comparison of the long-term outcomes of kidney transplantation: USA versus Spain[J]. Nephrol Dial Transplant, 2013, 28(1):213-220. DOI: 10.1093/ndt/gfs287.
    [63]
    THOMPSON B, TOWLER DA. Arterial calcification and bone physiology: role of the bone-vascular axis[J]. Nat Rev Endocrinol, 2012, 8(9):529-543. DOI: 10.1038/nrendo.2012.36.
    [64]
    RAGGI P, GIACHELLI C, BELLASI A. Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis[J]. Nat Clin Pract Cardiovasc Med, 2007, 4(1):26-33. doi: 10.1038/ncpcardio0725
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (231) PDF downloads(27) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return